REG - Psych Capital PLC - Admission to trading on AQSE

LMS CapitalAnnouncement

09/06/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220609:nRSI2230Oa&default-theme=true

RNS Number : 2230O  Psych Capital PLC  09 June 2022

Psych Capital Plc

("Psych Capital" or the "Company")

 

Admission to trading on AQSE

 

Psych Capital Plc, the psychedelic healthcare incubation and investment
company, that operates the leading industry  data, insights, and networking
platform, PSYCH, with over 20,000+ subscribers and over 3,000 delegates to
previous events, is pleased to announce that admission of its shares to
trading on the Aquis Stock Exchange Growth Market ("AQSE Growth Market") will
commence at 8.00a.m. today under the TIDM "PSY" and the ISIN number
GB00BL6CJQ54.

 

The Company's Admission Document is available at the Company's website:
(https://psych.capital) https://psych.capital (https://psych.capital)

 

Key Highlights

·    The Company currently has exposure to key segments of the medical
psychedelic sector through strategic acquisitions and investments, including:

·    Clinical research in connection with the development of psychedelic
medicines used to treat addiction;

·    Data collection in relation to developments in the psychedelic sector
(including, the legal framework, commerce and science); and

·    Media and communications platform for the medical psychedelic
industry

·    The Company intends to identify, fund and support the building of
future companies across three core pillars: therapeutic treatments, drug
development, and data/artificial intelligence

·    The Company will leverage its portfolio of brands, and network of
experts, to identify early-stage opportunities in the medical psychedelic
industry

·    The Psych Platform is a global B2B resource for networking,
intelligence, and insights, servicing the industry through publications,
newsletters and engaging events

·    PSYCH Symposium events generate strong revenue through sponsorship
and ticket sales.

 

Compelling Investment Proposition

Psych Capital is a publicly listed incubation and investment firm that deploys
early stage capital whilst building or supporting new companies in Europe's
psychedelic science and healthcare industry.

 

PSYCH is a data and intelligence platform for the psychedelic science and
healthcare industry. It has quickly become the industry's leading resource -
powered by trustworthy data, independent analysis and engaging events that
attract a highly influential audience of policy makers, scientists and
investors.

 

Market Opportunity

The nascent psychedelics' space is quickly being harnessed by a growing base
of institutional investors seeking to establish and scale businesses in a
landscape showing scientific and commercial promise.

 

·    Psych's offering aims to capitalise on the following market dynamics:

 

·    Numerous companies are currently creating training plans for
psychedelic therapists, including the MIND Foundation and COMPASS Pathway;

·    The United Nations (UN) Convention on Psychotropic Substances
framework for the international control of psychotropic substances lists:
Psilocybin, MDMA, DMT and LSD as Schedule I substances, the category
indicating the least harm with medical application;

·    Ketamine is on the WHO list of essential medicines;

·    Psilocybin therapy is expected to be a key driver in societal
education and a contributor to wider reforms across America;

·    MDMA-assisted therapy can take a strong market share from 2024;

·    Capital invested in psychedelic companies is over US$2 billion; and

·    The current value of medical businesses surpasses US$10 billion. For
example, ATAI Life Sciences' initial public offering (IPO) last year made it
the most valuable publicly-traded business in the sector, currently valued at
US$595 million.

 

Placing

The Company has raised gross proceeds of £810k from the issue and allotment
of 16,200,000 Placing Shares.

 

The Company intends to apply the net proceeds raised from the fundraising
activities to support its general working capital requirements and to develop
its existing business, whilst certain funds may be applied to enable the
Company to make further acquisitions.

 

Total voting rights

Following Admission, the total number of Ordinary Shares in issue will be
290,033,335 each with equal voting rights. The Company does not hold any
rights in treasury. The total voting rights figure can be used by Shareholders
as the denominator for the calculations by which they will determine whether
they are required to notify their interest in, or a change of their interest
in, the Company under the Disclosure Guidance and Transparency Rules of the
Financial Conduct Authority.

 

William Potts, Chief Investment Officer and Co-Founder of Psych Capital,
commented: "We're the first pure play Psychedelic company to list on a UK
stock market at an inflection point for the industry as global interest moves
towards the UK due to the leading science and companies here. We believe our
IPO is a milestone for the whole psychedelic industry in the UK.

 

"With an escalating global mental health crisis, there's a significant
opportunity for innovation to cater to unmet needs and improve patient
outcomes worldwide. Encouraged by breakthrough trials and science of
psychedelic-assisted therapy, our mission is to support a new wave of
innovators who are well positioned to challenge the status-quo and
revolutionise how society deals with mental health conditions."

 

The Directors of the Company accept responsibility for the contents of this
announcement.

 

For further information, please contact:

 

 Psych Capital Plc
 Stephen Murphy, Executive Director
 William Potts, Chief Investment Officer           info@PSYCH.capital (mailto:info@PSYCH.capital) or via Walbrook PR Ltd

                                                 psych@walbrookpr.com (mailto:psych@walbrookpr.com)

 AQSE Growth Market Corporate Adviser
 Peterhouse Capital Limited                        Tel: +44 (0) 207 469 0930
 Guy Miller / Mark Anwyl

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or psych@walbrookpr.com
 Nick Rome / Tom Cooper                            Mob: +44 (0) 7748 325 236 / +44 (0) 7971 221 972

 

 

About Psych Capital Plc

Psych Capital Plc identifies, funds and aims to support the building of
British and European companies across three core pillars: therapeutic
treatments, drug development, and data/AI. Its mission is to support a new
wave of innovators who are well positioned to challenge the status-quo and
revolutionise how society deals with mental health conditions.

 

Through a network of analysts with deep industry knowledge and capital markets
expertise, Psych Capital is focussed on developing a rigorously selected
portfolio of industry leading companies at the intersection of psychedelic
medicine and technology.

 

The Psych Platform is a business-to-business media and content platform for
the psychedelic science and healthcare industry, and it operates the website,
https://psych.global/ (https://psych.global/) . The Psych Platform is a global
B2B resource for networking, intelligence and insights, servicing the industry
through publications, newsletters and engaging events. The Psych Platform has
amassed a significant global B2B audience, with over 20,000 subscribers to the
platform.

 

As a business-to-business media and content platform, the Psych Platform also
produces the PSYCH Symposium, a premium Live Event series.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NEXBLGDLIXGDGDI